GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

Image Source: Zacks Investment Research The FDA approved Arexvy for use in adults in June 2024. Arexvy is currently approved in the United States, Europe, Japan and several other countries for ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Shares of GSK have gained 18.5% so far this year against the industry’s 0.1% decline. Image Source: Zacks Investment Research The FDA approved Arexvy for use in adults in June 2024. Arexvy is ...

Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between ...

which was approved last year for adults over the age of 60, generated a strong immune response in high-risk adults aged 18 and older. The FDA in June expanded the use of GSK's Arexvy vaccine in ...

The company said the results will be submitted for peer-reviewed scientific publication and will be used to support regulatory submissions to the FDA ... and older. AREXVY is approved for the ...